Alnylam Pharmaceuticals, Inc. and Akshay K. Vaishnaw, M.D., Ph.D. entered into a letter agreement, whereby Dr. Vaishnaw will leave his current position as President of the Company and transition to a part-time role as Chief Innovation Officer, effective October 2, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
150.1 USD | +1.56% | -0.12% | -21.60% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.60% | 18.69B | |
+54.05% | 63.85B | |
-2.02% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.42% | 26.52B | |
+2.89% | 12.73B | |
+22.40% | 12.11B | |
+27.49% | 12.07B | |
-9.26% | 11.19B |
- Stock Market
- Equities
- ALNY Stock
- News Alnylam Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals, Inc. Announces Management Changes, Effective October 2, 2023